BELITE BIO, INC (BLTE) Financial Statements
Free cash flow over the same period: -$37.2M.
Source: SEC EDGAR filings · read by EquiReason
BLTEBELITE BIO, INCFollow BLTE — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM | Trend |
|---|---|---|---|---|---|---|
| Research & development | 8.9 | 24.8 | 29.9 | 45.4 | — | |
| Operating income | -12.8 | -31.7 | -40.0 | -84.2 | — | |
| Pre-tax income | -12.6 | -31.6 | -36.1 | -77.6 | — | |
| Income tax | — | 0.0 | 0.0 | 0.0 | — | |
| Net income | -12.6 | -31.6 | -36.1 | -77.6 | — | |
| Diluted EPS ($) | -0.63 | -1.19 | -1.18 | -2.31 | — | |
| Diluted shares (mn) | 20.0 | 26.6 | 30.5 | 33.5 | — |
USD millions · SEC XBRL
BELITE BIO, INC — questions
- What is BELITE BIO, INC's net income?
- -$77.6M over the twelve months to .
- What is BELITE BIO, INC's free cash flow?
- -$37.2M over the twelve months to .
Every figure on this page comes from BELITE BIO, INC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.